ARORAGE-1001 is an ongoing phase 1/2a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-RAGE in normal healthy volunteers and asthma patients (NCT05276570). The gene discussed is AGER; the disease is asthma.